- Home
- OMCC vs AXDX Comparison
OMCC vs AXDX Comparison
Compare OMCC & AXDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMCC
- AXDX
- Stock Information
- Founded
- OMCC 1985
- AXDX 1982
- Country
- OMCC United States
- AXDX United States
- Employees
- OMCC N/A
- AXDX N/A
- Industry
- OMCC
- AXDX Biotechnology: Laboratory Analytical Instruments
- Sector
- OMCC
- AXDX Industrials
- Exchange
- OMCC NYSE
- AXDX Nasdaq
- Market Cap
- OMCC 43.4M
- AXDX 41.8M
- IPO Year
- OMCC N/A
- AXDX 1996
- Fundamental
- Price
- OMCC $6.05
- AXDX $1.16
- Analyst Decision
- OMCC
- AXDX Hold
- Analyst Count
- OMCC 0
- AXDX 1
- Target Price
- OMCC N/A
- AXDX $1.00
- AVG Volume (30 Days)
- OMCC 17.8K
- AXDX 72.5K
- Earning Date
- OMCC 02-11-2025
- AXDX 11-07-2024
- Dividend Yield
- OMCC N/A
- AXDX N/A
- EPS Growth
- OMCC N/A
- AXDX N/A
- EPS
- OMCC N/A
- AXDX N/A
- Revenue
- OMCC $22,181,000.00
- AXDX $11,909,000.00
- Revenue This Year
- OMCC N/A
- AXDX $1.50
- Revenue Next Year
- OMCC N/A
- AXDX $4.17
- P/E Ratio
- OMCC N/A
- AXDX N/A
- Revenue Growth
- OMCC N/A
- AXDX N/A
- 52 Week Low
- OMCC $5.29
- AXDX $0.73
- 52 Week High
- OMCC $7.55
- AXDX $4.41
- Technical
- Relative Strength Index (RSI)
- OMCC N/A
- AXDX 27.10
- Support Level
- OMCC N/A
- AXDX $1.12
- Resistance Level
- OMCC N/A
- AXDX $1.27
- Average True Range (ATR)
- OMCC 0.00
- AXDX 0.13
- MACD
- OMCC 0.00
- AXDX -0.03
- Stochastic Oscillator
- OMCC 0.00
- AXDX 5.26
About OMCC OLD MARKET CAPITAL CORPORATION
Old Market Capital Corp formerly Nicholas Financial Inc is a specialized consumer finance company. It is engaged in acquiring and servicing automobile finance installment contracts for purchases of used and new automobiles and light trucks. It also originates direct consumer loans and sells consumer-finance-related products. The majority of its revenue comes from Interest and fee income.
About AXDX Accelerate Diagnostics Inc.
Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.